Nearly one in ten Americans have an allergy to one or more foods, 32 million people. Peanuts, milk, and shellfish are among the most common trigger foods, and a reaction can range from mild (an itchy mouth after you eat the food) to severe (throat closing, difficulty breathing called anaphylaxis); in rare cases, a food allergy can be fatal if the patient doesn’t get treatment quickly enough. And food allergies are just one of the 7 allergies that are on the rise.
Allergy Therapeutics (LON:AGY) is an international commercial biotechnology group focused on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional fourteen countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.
